p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.
about
Immunologic aspect of ovarian cancer and p53 as tumor antigen.Whole Tumor Antigen Vaccines: Where Are We?Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedsideCombining Oncolytic Virotherapy with p53 Tumor Suppressor Gene TherapyGene therapy: development of immunostimulatory treatments for cancer.Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus AnkaraApplications of pox virus vectors to vaccination: an update.Systemic distribution and tumor localization of adoptively transferred lymphocytes in mice: comparison with physiologically based pharmacokinetic model.The role of p53 in the immunobiology of cutaneous squamous cell carcinoma.Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis.Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope.Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma.Genetically engineered poxviruses for recombinant gene expression, vaccination, and safetySerum autoantibodies as biomarkers for early cancer detection.E1B 55-kilodalton oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p53.Inactivation of p53 but not p73 by adenovirus type 5 E1B 55-kilodalton and E4 34-kilodalton oncoproteins.Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion.Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients.Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.Replication-deficient vaccinia virus gene therpay vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells.Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2).Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.Putting p53 in Context.Humoral immune response to p53 in malignant glioma.Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer.[Autoantibodies as the early diagnostic biomarkers for lung cancer].
P2860
Q24814703-71128C77-C4EC-4DD8-B7E2-72F663059702Q26783866-A6F7F2EB-A8A2-4BFA-A70E-0AA6E443838BQ27015695-E5E8336B-B238-44DE-A390-361DA1A13DE1Q33633277-E47454A3-1B4F-4BB3-B063-EA433633D157Q34187915-CF7682CD-276C-4C90-9AEA-9C4863185C0EQ34343169-5541A64D-EAEC-4276-9698-0340188FE841Q34403246-99A9F048-D5D8-4645-81B0-A3DB607F0866Q34775046-97F42257-09E5-4B73-BC87-DE34562AE110Q35142669-98FB1AC4-2F8D-4213-B0F5-B5DB032BF098Q35946213-1F6108ED-E035-4994-872B-B11516F8D221Q36169087-EC811BC8-8D63-4258-894A-D6DF3E1C982DQ36376876-B681963F-D1EA-402C-89A9-E8128EE8CF25Q36380515-E0E0CDDB-CB2D-4836-B8AC-33B29D20E40CQ36401780-48E49E6E-A558-4E4F-A76A-24DA4B911638Q36496709-2EF93365-ECCE-45A7-B881-2AFFF72E2C56Q37249251-02911933-0FA3-4B0F-A013-94C0CFDFDDB4Q37622471-487C5436-356F-4681-9152-8EC31389D4EFQ38317803-CB0F3A1C-B515-4FC0-95DC-1D6764F54E7EQ38332683-C73A6A29-8B64-4121-8AD6-A68B12C724A7Q39597953-6032DBF1-7908-46E2-AC70-3ABE4D051A9DQ40555883-2D5141D5-7EA2-46B6-B378-FD71A16C7AF3Q40812116-5B09AE1A-D35A-4F75-90ED-6FC27269272EQ40903376-6814BEC3-D854-4B44-8938-615465E2306CQ43767316-569770DF-B562-4ACE-A35C-048D202349BCQ45870268-7E9B5FED-4864-4D70-8214-3CF4778FD506Q45887190-65A0ACF3-E489-4A15-A652-AD94CBD803A3Q46343726-D8C2AE05-0FD6-47FC-B3E3-4FDD59DEBAB5Q47833426-01FE6A0F-7926-44AC-8E77-482B89FB27CFQ48485772-EFA731D1-B3E9-4042-87B6-20C50129F910Q52021863-B950270D-4CB8-4DEE-9E9A-9AAEF40B7ED1Q55436520-B82A168D-5050-4E46-93E2-784E9EE4C6CD
P2860
p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
p53 as a target for cancer vac ...... t lethal tumor cell challenge.
@en
p53 as a target for cancer vac ...... t lethal tumor cell challenge.
@nl
type
label
p53 as a target for cancer vac ...... t lethal tumor cell challenge.
@en
p53 as a target for cancer vac ...... t lethal tumor cell challenge.
@nl
prefLabel
p53 as a target for cancer vac ...... t lethal tumor cell challenge.
@en
p53 as a target for cancer vac ...... t lethal tumor cell challenge.
@nl
P2093
P2860
P356
P1476
p53 as a target for cancer vac ...... st lethal tumor cell challenge
@en
P2093
P2860
P304
P356
10.1073/PNAS.93.10.4781
P407
P577
1996-05-01T00:00:00Z